Does the media favor KPTI or CGEM?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.94 beat Cullinan Therapeutics' score of 0.60 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABUS or KPTI?

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 2 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.94 beat Arbutus Biopharma's score of 0.93 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KPTI or PHAT more profitable?

Phathom Pharmaceuticals has a net margin of -76.77% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics -129.02% N/A -120.29% Phathom Pharmaceuticals -76.77% N/A -44.29%

Does the media favor KPTI or PHAT?

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.94 beat Phathom Pharmaceuticals' score of 0.63 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Karyopharm Therapeutics (KPTI) Competitors

$10.22 +0.01 (+0.05%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$10.15 -0.06 (-0.64%)

As of 05:02 AM Eastern

Compare

KPTI vs. TBPH, ORIC, CGEM, ABUS, and PHAT

Should you buy Karyopharm Therapeutics stock or one of its competitors? MarketBeat compares Karyopharm Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Karyopharm Therapeutics include Theravance Biopharma (TBPH), Oric Pharmaceuticals (ORIC), Cullinan Therapeutics (CGEM), Arbutus Biopharma (ABUS), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.

How does Karyopharm Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Theravance Biopharma has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$109.78M	8.28	$105.89M	$2.20	8.01
Karyopharm Therapeutics	$151.12M	1.53	-$196.04M	-$15.09	N/A

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 1 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 0.94 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Theravance Biopharma	Very Positive
Karyopharm Therapeutics	Positive

Theravance Biopharma presently has a consensus target price of $21.40, indicating a potential upside of 21.38%. Karyopharm Therapeutics has a consensus target price of $17.17, indicating a potential upside of 68.05%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Theravance Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Karyopharm Therapeutics' net margin of -129.02%. Theravance Biopharma's return on equity of 18.84% beat Karyopharm Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Summary

Theravance Biopharma beats Karyopharm Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 1 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Karyopharm Therapeutics' score of 0.94 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Very Positive
Karyopharm Therapeutics	Positive

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Oric Pharmaceuticals has higher earnings, but lower revenue than Karyopharm Therapeutics. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Karyopharm Therapeutics	$151.12M	1.53	-$196.04M	-$15.09	N/A

Oric Pharmaceuticals currently has a consensus price target of $18.92, indicating a potential upside of 98.50%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 68.05%. Given Oric Pharmaceuticals' higher probable upside, equities research analysts plainly believe Oric Pharmaceuticals is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Oric Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Summary

Oric Pharmaceuticals beats Karyopharm Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Cullinan Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Karyopharm Therapeutics presently has a consensus target price of $17.17, indicating a potential upside of 68.05%. Cullinan Therapeutics has a consensus target price of $32.00, indicating a potential upside of 73.91%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cullinan Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Karyopharm Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$151.12M	1.53	-$196.04M	-$15.09	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.94 beat Cullinan Therapeutics' score of 0.60 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Karyopharm Therapeutics and Cullinan Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Arbutus Biopharma has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	64.05	-$33.50M	$0.83	5.50
Karyopharm Therapeutics	$151.12M	1.53	-$196.04M	-$15.09	N/A

Arbutus Biopharma currently has a consensus price target of $5.00, suggesting a potential upside of 9.53%. Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 68.05%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 2 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.94 beat Arbutus Biopharma's score of 0.93 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma has a net margin of 83.95% compared to Karyopharm Therapeutics' net margin of -129.02%. Arbutus Biopharma's return on equity of 129.32% beat Karyopharm Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Arbutus Biopharma has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Summary

Arbutus Biopharma and Karyopharm Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Phathom Pharmaceuticals?

Karyopharm Therapeutics (NASDAQ:KPTI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Karyopharm Therapeutics presently has a consensus target price of $17.17, indicating a potential upside of 68.05%. Phathom Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 128.54%. Given Phathom Pharmaceuticals' higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Karyopharm Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$151.12M	1.53	-$196.04M	-$15.09	N/A
Phathom Pharmaceuticals	$175.11M	4.88	-$221.25M	-$2.12	N/A

Karyopharm Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 2 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.94 beat Phathom Pharmaceuticals' score of 0.63 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Phathom Pharmaceuticals beats Karyopharm Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$231.39M	$3.02B	$6.83B	$12.17B
Dividend Yield	N/A	1.88%	2.66%	6.11%
P/E Ratio	-0.68	19.54	25.89	24.17
Price / Sales	1.53	330.40	547.76	101.00
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	-0.64	4.21	10.75	6.38
Net Income	-$196.04M	$64.45M	$3.58B	$337.00M
7 Day Performance	13.50%	1.32%	1.97%	-0.20%
1 Month Performance	12.25%	-1.07%	-0.24%	-1.40%
1 Year Performance	132.69%	29.70%	34.39%	27.76%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	2.2685 of 5 stars	$10.22 +0.0%	$17.17 +68.1%	+132.7%	$231.39M	$151.12M	N/A	380	Gap Down High Trading Volume
TBPH Theravance Biopharma	3.4698 of 5 stars	$16.32 -1.9%	$21.83 +33.8%	+57.1%	$857.84M	$107.46M	7.42	110	Positive News
ORIC Oric Pharmaceuticals	2.3386 of 5 stars	$8.40 +1.6%	$18.92 +125.2%	-7.6%	$856.09M	N/A	N/A	80	Positive News
CGEM Cullinan Therapeutics	2.6857 of 5 stars	$13.61 -0.7%	$32.00 +135.1%	+137.1%	$841.97M	N/A	N/A	30
ABUS Arbutus Biopharma	1.22 of 5 stars	$4.32 +1.4%	$5.00 +15.7%	+45.8%	$841.51M	$14.08M	5.20	90	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. TBPH, ORIC, CGEM, ABUS, and PHAT

How does Karyopharm Therapeutics compare to Theravance Biopharma?

Summary

How does Karyopharm Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Karyopharm Therapeutics compare to Cullinan Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Arbutus Biopharma?

Summary

How does Karyopharm Therapeutics compare to Phathom Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. TBPH, ORIC, CGEM, ABUS, and PHAT

How does Karyopharm Therapeutics compare to Theravance Biopharma?

Which has preferable valuation & earnings, TBPH or KPTI?

Do insiders & institutionals believe in TBPH or KPTI?

Does the media prefer TBPH or KPTI?

Do analysts rate TBPH or KPTI?

Which has more volatility and risk, TBPH or KPTI?

Is TBPH or KPTI more profitable?

Summary

How does Karyopharm Therapeutics compare to Oric Pharmaceuticals?

Does the media favor ORIC or KPTI?

Do institutionals and insiders believe in ORIC or KPTI?

Is ORIC or KPTI more profitable?

Which has stronger valuation and earnings, ORIC or KPTI?

Do analysts rate ORIC or KPTI?

Which has more risk & volatility, ORIC or KPTI?

Summary

How does Karyopharm Therapeutics compare to Cullinan Therapeutics?

Do analysts recommend KPTI or CGEM?

Is KPTI or CGEM more profitable?

Which has better earnings & valuation, KPTI or CGEM?

Does the media favor KPTI or CGEM?

Which has more risk and volatility, KPTI or CGEM?

Do institutionals & insiders believe in KPTI or CGEM?

Summary

How does Karyopharm Therapeutics compare to Arbutus Biopharma?

Which has higher earnings and valuation, ABUS or KPTI?

Do analysts prefer ABUS or KPTI?

Does the media prefer ABUS or KPTI?

Do institutionals and insiders believe in ABUS or KPTI?

Is ABUS or KPTI more profitable?

Which has more volatility & risk, ABUS or KPTI?

Summary

How does Karyopharm Therapeutics compare to Phathom Pharmaceuticals?

Do insiders and institutionals believe in KPTI or PHAT?

Is KPTI or PHAT more profitable?

Do analysts recommend KPTI or PHAT?

Which has stronger earnings and valuation, KPTI or PHAT?

Which has more risk & volatility, KPTI or PHAT?

Does the media favor KPTI or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools